19 September 2022>: Clinical Research
Circulating Methylated DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal Cancer
Zhen Yuan 12ABCEF* , Shuyuan Wang 12ABCDEF* , Kemin Ni 12ACDF* , Yixiang Zhan 12ACDF* , Hong Ma 1BDF , Xinyu Liu 13ABC , Ran Xin 2ABC , Xingyu Zhou 2BC , Zhaoce Liu 12BC , Xuanzhu Zhao 14BC , Xin Yin 2BC , Hangyu Ping 2BC , Yaohong Liu 2BC , Wanting Wang 4BC , Suying Yan 4BC , Qiurong Han 4BC , Wei Cui 5CD , Xipeng Zhang 167ADF , Qinghuai Zhang 167ABCD* , Chunze Zhang 167ABCDEFG*DOI: 10.12659/MSM.937757
Med Sci Monit 2022; 28:e937757
Figure 4 Recurrence-free survival stratified by longitudinal mSEPT9 (A) and further stratified by chemotherapy regimens (FOLFOX/CAPEOX) in patients with longitudinal positive mSEPT9 (B) and in those with longitudinal negative mSEPT9 (C). (D) Comparison of time to recurrence detected by mSEPT9 and radiology (p<0.001). R software 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria) was used for Figure creation.